SlideShare uma empresa Scribd logo
1 de 20
Moscow State University Faculty of Basic Medicine Presented by Dr.Chan Myae Htut (M.B.B.S) Supervisors – Prof Dr. B.I.Polyakov,Dr.D.A.Bykov May 19,2010 CHOP CHEMOTHERAPY PLUS RITUXIMAB COMPARED WITH CHOP ALONE IN ELDERY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
INTRODUCTION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ETIOLOGY AND PATHOGENESIS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CLINICAL FEATURES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
DIAGNOSIS ,[object Object],[object Object],[object Object],[object Object]
Therapy(In patients older than 60 years) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
AIM OF STUDY ,[object Object]
OBJECTIVE OF STUDY ,[object Object],[object Object]
DESIGN OF STUDY 52 PATIENTS 27 PATIENTS R-CHOP 25 PATIENTS CHOP 27 PATIENTS R-CHOP
 
MAIN CHARACTERISTICS OF PATIENTS (N=52) CHARACTERISTICS R-CHOP (N=27) NO(%) CHOP (N=25) NO(%) Age <65 yrs 65 – 69 yrs 70 -74 yrs > 74 yrs 6 (22) 8 (28) 7 (26) 6 (22) 6 (24) 8 (31) 7 (28)  4 (16) Male Sex 12 (46) 16 (54) Performance Status 0 1 > 1 9 (33) 12 (45) 6 (22) 9 (36) 12 (48) 4 (17) B symptoms 11 (39) 9 (36) Stage I II III IV 0  5 (20) 4 (16) 18 (63) 0 5 (20) 4 (15) 16 (65)
MAIN CHARACTERISTICS OF PATIENTS (N=52) (Contd.) CHARACTERISTICS R-CHOP (N=27) NO(%) CHOP (N=25) NO (%) No of extra nodal sites 0 1 >2 6 (23) 13 (47) 8 (30) 6  (22) 12 (52) 7 (26) Bulky tumour (>10cm) 8 (30) 8 (32) Bone marrow involvement 8 (30) 7 (28) Standard International Prognostic Index Score 0-1 2 3 4-5 4 (16) 9 (32) 11 (39) 3 (15) 3 (12) 9 (35) 10 (42) 3 (12)
RESPONSE TO TREATMENT RESPONSE R-CHOP (N=27) NO(%) CHOP (N=25) NO(%) Complete response Unconfirmed complete response Partial response Progressive disease Death without progression 14 (52) 6 (23) 2 (7) 3 (9) 2 (6) 9 (37) 7 (26) 2 (6) 5 (22) 2 (1)
EVENT FREE SURVIVAL
OVERALL SURVIVAL
NONHEMATOLOGIC ADVERSE EVENTS
NONHEMATOLOGIC ADVERSE EVENTS(Contd.)
DISCUSSION ,[object Object],[object Object],[object Object]
CONCLUSION ,[object Object],[object Object]
 

Mais conteúdo relacionado

Mais procurados

Discoidin receptors a proteomic portret
Discoidin receptors a proteomic portretDiscoidin receptors a proteomic portret
Discoidin receptors a proteomic portret
Maciej Luczynski
 
Ong et al._Translational utility of next-generation sequencing_2013_Genomics
Ong et al._Translational utility of next-generation sequencing_2013_GenomicsOng et al._Translational utility of next-generation sequencing_2013_Genomics
Ong et al._Translational utility of next-generation sequencing_2013_Genomics
Frank Ong, MD, CPI
 
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...
European School of Oncology
 
Clinical Cancer Research Publication
Clinical Cancer Research PublicationClinical Cancer Research Publication
Clinical Cancer Research Publication
David W. Salzman
 

Mais procurados (20)

Biochemical and cellular implications of drug resistant malaria
Biochemical and cellular implications of drug resistant malariaBiochemical and cellular implications of drug resistant malaria
Biochemical and cellular implications of drug resistant malaria
 
An evaluation of the clinical utility of a panel of variants in DPYD and ENOS...
An evaluation of the clinical utility of a panel of variants in DPYD and ENOS...An evaluation of the clinical utility of a panel of variants in DPYD and ENOS...
An evaluation of the clinical utility of a panel of variants in DPYD and ENOS...
 
3 gvt effect
3 gvt effect3 gvt effect
3 gvt effect
 
Discoidin receptors a proteomic portret
Discoidin receptors a proteomic portretDiscoidin receptors a proteomic portret
Discoidin receptors a proteomic portret
 
Ong et al._Translational utility of next-generation sequencing_2013_Genomics
Ong et al._Translational utility of next-generation sequencing_2013_GenomicsOng et al._Translational utility of next-generation sequencing_2013_Genomics
Ong et al._Translational utility of next-generation sequencing_2013_Genomics
 
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...
ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...
 
Dr. David Mooney - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. David Mooney - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. David Mooney - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. David Mooney - Simposio Internacional 'Terapias oncológicas avanzadas'
 
The Potent ALK Inhibitor Brigtanib (AP26613) Overcomes Mechanisms of Resistan...
The Potent ALK Inhibitor Brigtanib (AP26613) Overcomes Mechanisms of Resistan...The Potent ALK Inhibitor Brigtanib (AP26613) Overcomes Mechanisms of Resistan...
The Potent ALK Inhibitor Brigtanib (AP26613) Overcomes Mechanisms of Resistan...
 
ncomms11428
ncomms11428ncomms11428
ncomms11428
 
Ideal induction therapy for newly diagnosed AML. Do we have a consensus?
Ideal induction therapy for newly diagnosed AML. Do we have a consensus?Ideal induction therapy for newly diagnosed AML. Do we have a consensus?
Ideal induction therapy for newly diagnosed AML. Do we have a consensus?
 
Prognostic and clinicopathological significance of programmed death ligand 1 ...
Prognostic and clinicopathological significance of programmed death ligand 1 ...Prognostic and clinicopathological significance of programmed death ligand 1 ...
Prognostic and clinicopathological significance of programmed death ligand 1 ...
 
npjsba201634-2
npjsba201634-2npjsba201634-2
npjsba201634-2
 
Necitumumab imc 11 f8 ott 2010
Necitumumab imc 11 f8 ott 2010Necitumumab imc 11 f8 ott 2010
Necitumumab imc 11 f8 ott 2010
 
The Prognostic Value of Nucleolar Organiser Regions in Colorectal Cancer
The Prognostic Value of Nucleolar Organiser Regions in Colorectal CancerThe Prognostic Value of Nucleolar Organiser Regions in Colorectal Cancer
The Prognostic Value of Nucleolar Organiser Regions in Colorectal Cancer
 
Metanalisys
MetanalisysMetanalisys
Metanalisys
 
Clinical Cancer Research Publication
Clinical Cancer Research PublicationClinical Cancer Research Publication
Clinical Cancer Research Publication
 
genomics upenn publication 1
genomics upenn publication 1genomics upenn publication 1
genomics upenn publication 1
 
Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....
Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....
Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....
 
Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...
Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...
Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...
 
Vorinostat combined with DNMTi epigenetically controls the proliferation of l...
Vorinostat combined with DNMTi epigenetically controls the proliferation of l...Vorinostat combined with DNMTi epigenetically controls the proliferation of l...
Vorinostat combined with DNMTi epigenetically controls the proliferation of l...
 

Destaque

Українська онлайн спільнота
Українська онлайн спільнотаУкраїнська онлайн спільнота
Українська онлайн спільнота
bohdan tarlupa
 
Mazanick final presentation
Mazanick final presentation Mazanick final presentation
Mazanick final presentation
mariaksandberg
 
Dlt storyboard 5.17.10
Dlt storyboard 5.17.10Dlt storyboard 5.17.10
Dlt storyboard 5.17.10
mariaksandberg
 
Lesson Plan For IIT
Lesson Plan For IITLesson Plan For IIT
Lesson Plan For IIT
lswvivian
 
Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)
zawhtet1984
 
'S artistic gmpd supplementary code of points 10 february 2010 (1)
'S artistic gmpd supplementary code of points 10 february 2010 (1)'S artistic gmpd supplementary code of points 10 february 2010 (1)
'S artistic gmpd supplementary code of points 10 february 2010 (1)
EmmaHJ
 

Destaque (18)

Bedrijfspresentatie R&amp;S Multicleaning
Bedrijfspresentatie R&amp;S MulticleaningBedrijfspresentatie R&amp;S Multicleaning
Bedrijfspresentatie R&amp;S Multicleaning
 
Українська онлайн спільнота
Українська онлайн спільнотаУкраїнська онлайн спільнота
Українська онлайн спільнота
 
Mazanick final presentation
Mazanick final presentation Mazanick final presentation
Mazanick final presentation
 
Congresso SIGO 2011| L'età conquistata dalla donna
Congresso SIGO 2011| L'età conquistata dalla donnaCongresso SIGO 2011| L'età conquistata dalla donna
Congresso SIGO 2011| L'età conquistata dalla donna
 
Yehlaingbwar
YehlaingbwarYehlaingbwar
Yehlaingbwar
 
Eat more greens
Eat more greensEat more greens
Eat more greens
 
Dlt storyboard 5.17.10
Dlt storyboard 5.17.10Dlt storyboard 5.17.10
Dlt storyboard 5.17.10
 
Seo Ranking Factors
Seo Ranking FactorsSeo Ranking Factors
Seo Ranking Factors
 
Ppt For Bit
Ppt For BitPpt For Bit
Ppt For Bit
 
Infokost promo mei_july_2010
Infokost promo mei_july_2010Infokost promo mei_july_2010
Infokost promo mei_july_2010
 
Over custom
Over customOver custom
Over custom
 
Lesson Plan For IIT
Lesson Plan For IITLesson Plan For IIT
Lesson Plan For IIT
 
Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)
 
Formazione in sessuologia
Formazione in sessuologiaFormazione in sessuologia
Formazione in sessuologia
 
L'endometriosi una ferita all'identità sessuale femminile
L'endometriosi una ferita all'identità sessuale femminileL'endometriosi una ferita all'identità sessuale femminile
L'endometriosi una ferita all'identità sessuale femminile
 
'S artistic gmpd supplementary code of points 10 february 2010 (1)
'S artistic gmpd supplementary code of points 10 february 2010 (1)'S artistic gmpd supplementary code of points 10 february 2010 (1)
'S artistic gmpd supplementary code of points 10 february 2010 (1)
 
La contraccezione
La contraccezioneLa contraccezione
La contraccezione
 
Educazione sessuale
Educazione sessualeEducazione sessuale
Educazione sessuale
 

Semelhante a Chan myae htut

Cco clin onc_june _2012_lymphoma_slides
Cco clin onc_june _2012_lymphoma_slidesCco clin onc_june _2012_lymphoma_slides
Cco clin onc_june _2012_lymphoma_slides
Adonis Guancia
 
Hodgkin’S And Non Hodgkin’S Lymphoma
Hodgkin’S And Non Hodgkin’S LymphomaHodgkin’S And Non Hodgkin’S Lymphoma
Hodgkin’S And Non Hodgkin’S Lymphoma
fondas vakalis
 
Powerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihaPowerpoint presentation by dr sathiha
Powerpoint presentation by dr sathiha
zawhtet1984
 
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patientsLLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
European School of Oncology
 
7 neelapu
7 neelapu7 neelapu
7 neelapu
spa718
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
European School of Oncology
 
Antibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute PanceriatitisAntibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute Panceriatitis
Saeed Al-Shomimi
 

Semelhante a Chan myae htut (20)

Cco clin onc_june _2012_lymphoma_slides
Cco clin onc_june _2012_lymphoma_slidesCco clin onc_june _2012_lymphoma_slides
Cco clin onc_june _2012_lymphoma_slides
 
Hodgkin’S And Non Hodgkin’S Lymphoma
Hodgkin’S And Non Hodgkin’S LymphomaHodgkin’S And Non Hodgkin’S Lymphoma
Hodgkin’S And Non Hodgkin’S Lymphoma
 
DLBCL- Recent Molecular Classification.pptx
DLBCL- Recent Molecular Classification.pptxDLBCL- Recent Molecular Classification.pptx
DLBCL- Recent Molecular Classification.pptx
 
Powerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihaPowerpoint presentation by dr sathiha
Powerpoint presentation by dr sathiha
 
Dr. Manuel Hidalgo - Simposio Internacional ' Terapias oncológicas avanzadas'
Dr. Manuel Hidalgo - Simposio Internacional ' Terapias oncológicas avanzadas'Dr. Manuel Hidalgo - Simposio Internacional ' Terapias oncológicas avanzadas'
Dr. Manuel Hidalgo - Simposio Internacional ' Terapias oncológicas avanzadas'
 
Roschewski-Mark-IV-hematology_forum_2016
Roschewski-Mark-IV-hematology_forum_2016Roschewski-Mark-IV-hematology_forum_2016
Roschewski-Mark-IV-hematology_forum_2016
 
V_Hematology_Forum_B_Afanasiev
V_Hematology_Forum_B_AfanasievV_Hematology_Forum_B_Afanasiev
V_Hematology_Forum_B_Afanasiev
 
Bendamustine Vs R-CHOP/R-CVP-Bright study
Bendamustine Vs R-CHOP/R-CVP-Bright studyBendamustine Vs R-CHOP/R-CVP-Bright study
Bendamustine Vs R-CHOP/R-CVP-Bright study
 
Lupus Nephritis Dilemma - Prof. Mohsen El Kosi
Lupus Nephritis Dilemma - Prof. Mohsen El KosiLupus Nephritis Dilemma - Prof. Mohsen El Kosi
Lupus Nephritis Dilemma - Prof. Mohsen El Kosi
 
Building Bridges Between Discovery, Preclinical, And Clinical Research 2008
Building Bridges Between Discovery, Preclinical, And Clinical Research 2008Building Bridges Between Discovery, Preclinical, And Clinical Research 2008
Building Bridges Between Discovery, Preclinical, And Clinical Research 2008
 
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patientsLLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients
 
Ohio State's ASH Review 2017 - Myeloproliferative Disorders
Ohio State's ASH Review 2017 - Myeloproliferative DisordersOhio State's ASH Review 2017 - Myeloproliferative Disorders
Ohio State's ASH Review 2017 - Myeloproliferative Disorders
 
New Treatments for Lupus by Daniel J. Wallace, MD
New Treatments for Lupus by Daniel J. Wallace, MDNew Treatments for Lupus by Daniel J. Wallace, MD
New Treatments for Lupus by Daniel J. Wallace, MD
 
S.c.l.c dr.hatem
S.c.l.c dr.hatemS.c.l.c dr.hatem
S.c.l.c dr.hatem
 
The Role of Radiotherapy in the Treatment of Early Stage Ocular Marginal Zone...
The Role of Radiotherapy in the Treatment of Early Stage Ocular Marginal Zone...The Role of Radiotherapy in the Treatment of Early Stage Ocular Marginal Zone...
The Role of Radiotherapy in the Treatment of Early Stage Ocular Marginal Zone...
 
Lenalidomide maintenance compared with placebo in responding elderly
Lenalidomide maintenance compared with placebo in responding elderlyLenalidomide maintenance compared with placebo in responding elderly
Lenalidomide maintenance compared with placebo in responding elderly
 
7 neelapu
7 neelapu7 neelapu
7 neelapu
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
Antibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute PanceriatitisAntibiotic prophylaxis in sever Acute Panceriatitis
Antibiotic prophylaxis in sever Acute Panceriatitis
 
Update on treatment for lymphoma, Lymphoma Support Ireland meeting - feb 2011...
Update on treatment for lymphoma, Lymphoma Support Ireland meeting - feb 2011...Update on treatment for lymphoma, Lymphoma Support Ireland meeting - feb 2011...
Update on treatment for lymphoma, Lymphoma Support Ireland meeting - feb 2011...
 

Mais de zawhtet1984

Tanl power point
Tanl power pointTanl power point
Tanl power point
zawhtet1984
 
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Aung myo zaw(nutrition in  preterm and congenital hypotrophy)Aung myo zaw(nutrition in  preterm and congenital hypotrophy)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
zawhtet1984
 

Mais de zawhtet1984 (8)

Tanl power point
Tanl power pointTanl power point
Tanl power point
 
Kyaw thura zaw
Kyaw thura zawKyaw thura zaw
Kyaw thura zaw
 
Zaw htet
Zaw htetZaw htet
Zaw htet
 
Sithu ko
Sithu koSithu ko
Sithu ko
 
Khant zaw aung
Khant zaw aungKhant zaw aung
Khant zaw aung
 
Aung thiha soe
Aung thiha soeAung thiha soe
Aung thiha soe
 
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Aung myo zaw(nutrition in  preterm and congenital hypotrophy)Aung myo zaw(nutrition in  preterm and congenital hypotrophy)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
 
Aung citt nyein
Aung citt nyeinAung citt nyein
Aung citt nyein
 

Último

1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
QucHHunhnh
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
KarakKing
 

Último (20)

SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Dyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxDyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptx
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structure
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
Spatium Project Simulation student brief
Spatium Project Simulation student briefSpatium Project Simulation student brief
Spatium Project Simulation student brief
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 

Chan myae htut

  • 1. Moscow State University Faculty of Basic Medicine Presented by Dr.Chan Myae Htut (M.B.B.S) Supervisors – Prof Dr. B.I.Polyakov,Dr.D.A.Bykov May 19,2010 CHOP CHEMOTHERAPY PLUS RITUXIMAB COMPARED WITH CHOP ALONE IN ELDERY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9. DESIGN OF STUDY 52 PATIENTS 27 PATIENTS R-CHOP 25 PATIENTS CHOP 27 PATIENTS R-CHOP
  • 10.  
  • 11. MAIN CHARACTERISTICS OF PATIENTS (N=52) CHARACTERISTICS R-CHOP (N=27) NO(%) CHOP (N=25) NO(%) Age <65 yrs 65 – 69 yrs 70 -74 yrs > 74 yrs 6 (22) 8 (28) 7 (26) 6 (22) 6 (24) 8 (31) 7 (28) 4 (16) Male Sex 12 (46) 16 (54) Performance Status 0 1 > 1 9 (33) 12 (45) 6 (22) 9 (36) 12 (48) 4 (17) B symptoms 11 (39) 9 (36) Stage I II III IV 0 5 (20) 4 (16) 18 (63) 0 5 (20) 4 (15) 16 (65)
  • 12. MAIN CHARACTERISTICS OF PATIENTS (N=52) (Contd.) CHARACTERISTICS R-CHOP (N=27) NO(%) CHOP (N=25) NO (%) No of extra nodal sites 0 1 >2 6 (23) 13 (47) 8 (30) 6 (22) 12 (52) 7 (26) Bulky tumour (>10cm) 8 (30) 8 (32) Bone marrow involvement 8 (30) 7 (28) Standard International Prognostic Index Score 0-1 2 3 4-5 4 (16) 9 (32) 11 (39) 3 (15) 3 (12) 9 (35) 10 (42) 3 (12)
  • 13. RESPONSE TO TREATMENT RESPONSE R-CHOP (N=27) NO(%) CHOP (N=25) NO(%) Complete response Unconfirmed complete response Partial response Progressive disease Death without progression 14 (52) 6 (23) 2 (7) 3 (9) 2 (6) 9 (37) 7 (26) 2 (6) 5 (22) 2 (1)
  • 18.
  • 19.
  • 20.